Mylan completes expansion of its transdermal patch facility in Vermont.
Mylan has completed an 85,000 ft2, three-story expansion project at its transdermal patch facility in St. Albans, Vermont. The facility, operated by Mylan Technologies Inc. (MTI), is a subsidiary of Mylan that focuses on transdermal drug delivery. Mylan's investment includes expanded R&D capabilities and additional manufacturing and laboratory space. In addition, Mylan is in the process of adding more than 160 new positions to its St. Albans-based workforce.
The 14-month expansion project has increased MTI's total operating space to more than 391,000 ft2.
Source: Mylan
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.